Novartis to Acquire Regulus for $1.7B, Advancing MicroRNA Therapies

Published on Spencer Knight via LinkedIn

Novartis is acquiring Regulus Therapeutics for up to $1.7 billion to expand its position in oligonucleotide and microRNA-based therapies. The deal includes $7.00 per share in cash upfront (approximately $800M), plus a $7.00 per share contingent value right tied to FDA approval of the anti-miR-17 therapy, rGLS4326 (farbarsuren), for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

This acquisition reflects a 274% premium to Regulus’ 60-day VWAP and marks a significant moment for RNA therapeutics. The deal is expected to close in the second half of 2025, pending regulatory clearance.

Read the full post on LinkedIn:

👉 Spencer Knight: Novartis makes $1.7B miRNA acquisition

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.